Berlin, Germany, January 27, 2009 - JPT Peptide Technologies GmbH
(JPT), a wholly-owned subsidiary of Jerini AG (FSE:JI4), announced
today the launch of its new product line: PepTrack(TM). Designed for
peptides in T-cell assays (ELISPOT, CFC, ICS and others), this
approach represents the most efficient technique for producing large
numbers of peptides simultaneously. In addition, PepTrack(TM)
production is in compliance with DIN ISO 9001:2008 and Good Clinical
Laboratory Practices.

JPT offers four delivery options for T-cell assays: 1) Fast Track for
proteome-wide T-cell epitope discovery programs 2) Research Track for
T-cell epitope mapping studies 3) Discovery Track for immune
monitoring applications and 4) Trial Track for vaccination trials.
The new product line combines JPT's proprietary technologies with its
in-depth knowledge of T-cell assays in discovery research and
clinical trials.

"Our clients' experience has shown that peptides with inappropriate
specifications can, potentially, not only jeopardize T-cell assay
performance, but also entire clinical studies," states Holger
Wenschuh, Managing Director at JPT. "Avoiding sources of false
positive T-cell response, eliminating toxic contaminants that inhibit
T-cell activation, and developing and validating reproducible
production processes have been the key drivers in the development of
this new product line."

As a worldwide leader in peptide research and production, JPT has now
increased its production capacity to more than 2 million peptides per
year.

About JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH is a leading provider of peptide-based
research tools for applications focusing on cellular and humoral
immune response monitoring, vaccine development, peptide biomarker
discovery, and enzyme profiling. Using its patented high-throughput
synthesis and screening platform, SPOT(TM), its peptide microarray
technology, PepStar(TM), PepMix(TM), a new approach for antigen
specific T-cell stimulation, and PepTrack(TM), a novel approach to
create peptide libraries for specific use in T-cell assays, JPT has
developed a series of innovative products and services to facilitate
the development of novel immunotherapies and immune-monitoring tools.
JPT's ability to produce highly complex peptide libraries coupled
with its peptide array technology enables, for the first time, the
discovery and profiling of B- and T-cell epitopes on a proteome-wide
level. In addition, this capability facilitates the development of
tools to monitor the immune status of diverse patient populations
suffering from infectious and autoimmune diseases, allergies, and
cancer. JPT is a wholly-owned subsidiary of Berlin-based Jerini AG.

For further information please contact:
JPT Peptide Technologies GmbH
Dr. Holger Wenschuh
Managing Director
Volmerstr. 5
12555 Berlin/Germany
Tel: +49 - 30 - 6392 7880
Fax: +49 - 30 - 6392 5501
E-mail: wenschuh@jpt.com
Web: www.jpt.com


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.
http://hugin.info/135931/R/1284929/287976.pdf


Copyright © Hugin AS 2009. All rights reserved.